Full-Time

Research Scientist II

Gene Editing, Durham NC

Posted on 9/6/2024

ReCode Therapeutics

ReCode Therapeutics

51-200 employees

Develops gene therapies for respiratory diseases

Biotechnology
Healthcare

Compensation Overview

$120k - $130kAnnually

Mid

Durham, NC, USA

Position is based in Durham; relocation provided for candidates not living in Durham.

Category
Biology Lab & Research
Biology & Biotech
Required Skills
R
Data Analysis
Requirements
  • PhD in molecular biology, cell biology, biological engineering or related discipline with 4 years of experience in postdoctoral research and/or industry.
  • Subject matter expertise, with a proven track record of publications/patents, in gene editing, with a broad knowledge of gene editing applications.
  • Hands-on experience using gene editing tools including next generation CRISPR systems (e.g. Prime or Base editors).
  • Deep expertise in analytic RNA or DNA assays to measure and analyze gene editing results.
  • Experience in utilizing bioinformatics tools and software for the analysis of gene editing readouts.
  • Experience in mammalian cell and tissue culturing is required.
  • Experience with viral or non-viral delivery platforms, preferably lipid nanoparticles (LNPs) (recommended).
  • Understanding of lung biology and/or rare lung disease (recommended).
  • Excellent verbal and written communication skills, with proven ability to write reports and/or articles for publication.
  • Advanced knowledge of statistical and genome analytical tools (GraphPad, R, SnapGene).
  • Excellent project leadership skills in driving for results and innovation; ability to execute within a matrixed organization.
  • Extremely organized and able to efficiently manage your time and workflow, including skillfully prioritizing both long-term projects and day-to-day responsibilities.
  • Highly collaborative, team-oriented, and considerate of the needs of others.
  • Desire to work in a fast-paced environment and contribute to developing the next generation of gene editing.
Responsibilities
  • Lead, design, and execute experiments using next-generation gene editing and epigenome editing strategies with CRISPR-based tools and beyond.
  • Advance gene correction applications for therapeutic and non-viral platform discovery projects through the design, implementation/optimization, and execution of molecular biology, cell biology, and NGS-based assays.
  • Support the discovery of novel LNP delivery solutions through in vitro and in vivo gene editing screens.
  • Work with primary in vitro cell culture disease models of lung epithelial cells.
  • Generate, manage, evaluate, and maintain critical data in a highly organized manner, providing statistical analysis and troubleshooting where appropriate.
  • Analyze and present experimental data to a wide range of audiences.
  • Trouble shoot and dissect published literature to find novel solutions to resolve technical and/or biological hurdles.
  • Contribute as a key member of a cross functional drug discovery team that includes gene correction, primary human biology, pharmacology, computational biology, bioanalytical, toxicology and formulation capabilities.
  • Prepare SOPs, keep excellent electronic lab notebook and record keeping entries, and prepare reports and/or manuscripts for publication.
  • Manage one or more direct reports; mentor additions to the team.

ReCode Therapeutics develops gene therapy solutions aimed at treating complex respiratory diseases, specifically cystic fibrosis and primary ciliary dyskinesia. Their approach involves utilizing advanced drug development techniques to create therapies that can effectively target and restore function in patients suffering from these conditions. Unlike many competitors, ReCode Therapeutics emphasizes rapid advancement through a deep understanding of regulatory pathways and clinical trial processes. The company's goal is to overcome challenges in delivering therapies directly to affected areas in the lungs, ultimately enhancing the quality of life for patients with unmet medical needs.

Company Stage

Grant

Total Funding

$338M

Headquarters

Dallas, Texas

Founded

2015

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

-7%

2 year growth

37%
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing CF therapeutics market offers strong opportunities for ReCode's treatments.
  • FDA's accelerated approval pathways could expedite ReCode's therapy approvals.
  • Advancements in LNP technology align with ReCode's delivery platform.

What critics are saying

  • Emerging competition from Vertex in the CF space poses a threat.
  • Scaling up SORT LNP platform for commercial production may present challenges.
  • Regulatory hurdles for gene editing therapies could delay approvals.

What makes ReCode Therapeutics unique

  • ReCode's SORT LNP platform enables precise delivery beyond the liver.
  • Focus on inhaled mRNA therapies for CF and PCD sets ReCode apart.
  • Strategic collaboration with Intellia enhances ReCode's gene editing capabilities.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE